AACR Annual Meeting | Conference

Anti-Proliferative Activity of Eribulin in Select Sarcoma Cell Lines

May 5th 2016

Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.

Dr. Xifeng Wu on Prognostic Factor of Obesity-Related Genes in RCC

May 4th 2016

Xifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).

Fred Schumacher on Genetic Risk Factors of Prostate Cancer

May 3rd 2016

Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that led to the identification of genetic risk factors of prostate cancer.

Wendy Setiawan on Pancreatic Cancer Incidence Across Ethnic Populations

May 2nd 2016

Wendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.

Dr. Van Morris on Nivolumab as a Potential Treatment for Patients With Anal Cancer

May 2nd 2016

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.

Thomas Dubensky on How ADU-S100 Activates STING

April 29th 2016

Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

Dr. Ribas on Triplet Regimens in Melanoma

April 29th 2016

Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses triplet therapies for patients with melanoma and the sequencing challenges associated with the approvals of additional agents in the field.

Dr. Rubin on Advantages With Whole-Exome Sequencing

April 28th 2016

Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

Dr. Demetri on the Evolving Field of Sarcoma

April 27th 2016

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the evolving and advancing field of sarcoma.

Dr. Kelly on the JAVELIN Solid Tumor Trial

April 22nd 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.

Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC

April 21st 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Entinostat/IL-2 Combination Active in Previously Untreated Renal Cell Carcinoma

April 20th 2016

More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

Dr. Ferris on CheckMate-141 Trial in Head and Neck Cancer

April 20th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Dr. Khleif on Next Steps to Take With Immunotherapy

April 19th 2016

Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

Using Multiple Biomarkers Improves Risk Prediction for Breast Cancer

April 19th 2016

The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.

Frontline Pembrolizumab Induces Durable Responses in Merkel Cell Carcinoma

April 19th 2016

Anti–PD-1 therapy in the first-line induced responses in more than half of patients with advanced Merkel cell carcinoma, with encouraging durability to the responses.

Dr. Berger on Noninvasive Screening Tool for CRC

April 19th 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).

Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer

April 19th 2016

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).

Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer

April 19th 2016

Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

PD-L1 Expression Assays Show Similar Performance for NSCLC

April 19th 2016

Three currently available assays for PD-L1 expression exhibited a high degree of correlation in a comparative study involving archived lung cancer tissue.

NEXT PAGE
PREVIOUS PAGE